AbbVie Inc. Files 8-K on Officer Changes and Financials

Ticker: ABBV · Form: 8-K · Filed: 2025-02-14T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, officer-changes, financials

Related Tickers: ABBV

TL;DR

AbbVie filed an 8-K on Feb 14th detailing exec changes and financial exhibits.

AI Summary

AbbVie Inc. filed an 8-K on February 14, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also includes Regulation FD disclosures and financial statements/exhibits, with the report date as of February 13, 2025.

Why It Matters

This filing provides crucial updates on AbbVie's corporate governance and executive appointments, which can impact investor confidence and strategic direction.

Risk Assessment

Risk Level: low — This is a routine 8-K filing detailing corporate governance and financial information, not indicating any immediate operational or financial distress.

Key Numbers

Key Players & Entities

FAQ

What specific officer positions were affected by the appointments or departures mentioned in the filing?

The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' but the specific names and positions are not detailed in the provided excerpt.

Are there any new compensatory arrangements for officers disclosed in this filing?

The filing lists 'Compensatory Arrangements of Certain Officers' as an item information, suggesting such details are included, though not explicitly stated in the excerpt.

What is the significance of the 'Regulation FD Disclosure' item?

This indicates that AbbVie is making public disclosures that could be considered material non-public information, ensuring fair disclosure to all investors.

What types of financial statements and exhibits are included with this 8-K filing?

The filing lists 'Financial Statements and Exhibits' as an item, but the specific nature of these documents is not detailed in the provided text.

What is AbbVie Inc.'s Standard Industrial Classification (SIC) code?

AbbVie Inc.'s SIC code is 2834, which corresponds to 'Pharmaceutical Preparations'.

From the Filing

0001104659-25-013467.txt : 20250214 0001104659-25-013467.hdr.sgml : 20250214 20250214073058 ACCESSION NUMBER: 0001104659-25-013467 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250213 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250214 DATE AS OF CHANGE: 20250214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 25623223 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 tm256372d1_8k.htm FORM 8-K false 0001551152 Common Stock, $0.01 Par Value ABBV 0001551152 2025-02-13 2025-02-13 0001551152 us-gaap:CommonStockMember exch:XNYS 2025-02-13 2025-02-13 0001551152 exch:XCHI us-gaap:CommonStockMember 2025-02-13 2025-02-13 0001551152 abbv:SeniorNotes0.750Percentdue2027Member exch:XNYS 2025-02-13 2025-02-13 0001551152 abbv:SeniorNotes2.125Percentdue2028Member exch:XNYS 2025-02-13 2025-02-13 0001551152 abbv:SeniorNotes2.625Percentdue2028Member exch:XNYS 2025-02-13 2025-02-13 0001551152 abbv:SeniorNotes2.125Percentdue2029Member exch:XNYS 2025-02-13 2025-02-13 0001551152 abbv:SeniorNotes1.250Percentdue2031Member exch:XNYS 2025-02-13 2025-02-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 13, 2025   ABBVIE INC. (Exact name of registrant as specified in its charter)   Delaware   001-35565   32-0375147 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.) ________________________________________________________________      1 North Waukegan Road   North Chicago , Illinois 60064-6400   (Address of principal executive offices)(Zip Code)    Registrant’s telephone number, including area code: ( 847 ) 932-7900   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange Chicago Stock Exchange 0.750% Senior Notes due 2027   ABBV27   New York Stock Exchange 2.125% Senior Notes due 2028   ABBV28   New York Stock Exchange 2.625% Senior Notes due 2028   ABBV28B   New York Stock Exchange 2.125% Senior Notes due 2029   ABBV29   New York Stock Exchange 1.250% Senior Notes due 2031   ABBV31   New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securit

View on Read The Filing